GCP
XBIT icon

GSA Capital Partners’s XBiotech XBIT Stock Holding History

GSA Capital Partners’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,115
Closed -$162K – 1945
2016
Q1 		$162K Buy
17,115
+2,400
+16% +$19.9K 0.01% 1534
2015
Q4 		$160K Buy
+14,715
New +$188K 0.01% 1684

Other funds holding XBIT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
IG
ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GSA Capital Partners's XBIT Position: Q2 2016 in Review

GSA Capital Partners sold out of XBiotech (XBIT) in Q2 2016, closing a stake of 17,115 shares — an estimated $162K sold.

GSA Capital Partners first reported a position in XBIT in Q4 2015 and held it in 2 quarters. The position peaked at $162K in Q1 2016. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2016.

  • GSA Capital Partners reported no remaining XBiotech position as of Q2 2016 after selling out during the quarter.
  • GSA Capital Partners sold 17,115 XBiotech shares in Q2 2016, an estimated $162K.
  • GSA Capital Partners first reported a position in XBiotech in Q4 2015 and held it in 2 quarters.
  • GSA Capital Partners's XBiotech position peaked at $162K in Q1 2016.
  • 46 funds tracked by Wall St. Rank held XBiotech as of Q2 2016.

Based on GSA Capital Partners's 13F filing for Q2 2016, filed 4 Aug 2016.